Lauren Martz

Steve Usdin, Washington editor covering policy and FDA moves. Lauren Martz, oncology biomarker and cell therapy development expert. Paul Benanos, dealmaking and cell therapy commercialization analyst. They discuss Gilead’s $7.8B acquisition of Arcellx and its implications. They explore ctDNA as a potential surrogate endpoint and the validation, standardization and trial hurdles that remain.

Lauren Martz, Executive Director of Biopharma Intelligence, leads a discussion on the latest trends in pharmaceutical deals, revealing that bispecifics and degraders are gaining traction while cell and gene therapies are losing favor. Selena Koch, Executive Editor, shares insights from a recent conversation with Denali about advancements in brain shuttles. Karen Koch-Tusman highlights a groundbreaking FDA approval for a vector-based immunotherapy, suggesting potential new standards for treating rare diseases. Chinese biotech's growing influence is also addressed.

This week, Steve Usdin, Washington editor, and Lauren Martz, Biopharma Intelligence Executive Director, dive into the hot topics of biotech. They analyze significant deals from the J.P. Morgan Healthcare Conference, including a bispecific partnership between AbbVie and RemeGen. Usdin provides a bold policy outlook, warning of changes to drug pricing norms and potential FDA staff losses. Martz discusses approval trends for 2025, emphasizing innovations in drug delivery and the unique pressures affecting orphan drug programs. Tune in for new insights on biopharma dynamics!

Stephen Hansen, Director of Biopharma Intelligence at BioCentury, discusses innovative obesity therapies focusing on quality weight loss that preserves lean mass. Meanwhile, Lauren Martz, Executive Director of Biopharma Intelligence, dives into the potential impacts of Vinay Prasad's leadership at the FDA, particularly on regulatory approvals for biotech investors. They also introduce insights on ovarian cancer through large-scale molecular profiling, shedding light on predictive signatures that could enhance treatment strategies.

Simone Fishburn, Editor in Chief of BioCentury, Selina Koch, Executive Editor, and Lauren Martz, Executive Director of Biopharma Intelligence, discuss major trends in biopharma. They highlight the shift towards human-first, causal biology aimed at improving drug translation. Key topics include immunoproteomics outpacing genomics in inflammation and immunology target discovery. The trio also explores advancements in neuroscience, emphasizing how precision medicine can validate targets using biomarkers, ultimately reshaping clinical approaches in drug development.